| (Values in U.S. Thousands) | Dec, 2015 | Dec, 2011 | Mar, 2018 | Dec, 2017 | Sep, 2017 |
| Sales | 16,250 | 16,240 | 0 | 0 | 0 |
| Sales Growth | +0.06% | unch | unch | unch | unch |
| Net Income | -810 | -800 | 0 | 0 | 0 |
| Net Income Growth | -1.25% | unch | unch | unch | unch |
Hemacare Corp (HEMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
HEMACARE CORP.'s business activities include blood management programs, regional sales of blood products and blood services. Their Blood Management Programs enable hospitals to contract out all or a portion of their blood services activities, which include donor center management, blood procurement and other blood related activities. Blood Products include apheresis platelets and whole blood components, such as red blood cells and plasma products. Blood Services include therapeutic apheresisprocedures, stem cell collection and donor testing services.
Fiscal Year End Date: 12/31